Correlation Between Cardio Diagnostics and Effector Therapeutics
Can any of the company-specific risk be diversified away by investing in both Cardio Diagnostics and Effector Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cardio Diagnostics and Effector Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cardio Diagnostics Holdings and Effector Therapeutics, you can compare the effects of market volatilities on Cardio Diagnostics and Effector Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cardio Diagnostics with a short position of Effector Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cardio Diagnostics and Effector Therapeutics.
Diversification Opportunities for Cardio Diagnostics and Effector Therapeutics
-0.38 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Cardio and Effector is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Cardio Diagnostics Holdings and Effector Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Effector Therapeutics and Cardio Diagnostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cardio Diagnostics Holdings are associated (or correlated) with Effector Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Effector Therapeutics has no effect on the direction of Cardio Diagnostics i.e., Cardio Diagnostics and Effector Therapeutics go up and down completely randomly.
Pair Corralation between Cardio Diagnostics and Effector Therapeutics
Assuming the 90 days horizon Cardio Diagnostics Holdings is expected to generate 7.87 times more return on investment than Effector Therapeutics. However, Cardio Diagnostics is 7.87 times more volatile than Effector Therapeutics. It trades about 0.09 of its potential returns per unit of risk. Effector Therapeutics is currently generating about -0.04 per unit of risk. If you would invest 7.20 in Cardio Diagnostics Holdings on September 12, 2024 and sell it today you would lose (1.31) from holding Cardio Diagnostics Holdings or give up 18.19% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 98.71% |
Values | Daily Returns |
Cardio Diagnostics Holdings vs. Effector Therapeutics
Performance |
Timeline |
Cardio Diagnostics |
Effector Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Cardio Diagnostics and Effector Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Cardio Diagnostics and Effector Therapeutics
The main advantage of trading using opposite Cardio Diagnostics and Effector Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cardio Diagnostics position performs unexpectedly, Effector Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will offset losses from the drop in Effector Therapeutics' long position.Cardio Diagnostics vs. Cardio Diagnostics Holdings | Cardio Diagnostics vs. Revelation Biosciences | Cardio Diagnostics vs. LMF Acquisition Opportunities | Cardio Diagnostics vs. OmniAb Inc |
Effector Therapeutics vs. Indaptus Therapeutics | Effector Therapeutics vs. Jasper Therapeutics | Effector Therapeutics vs. RenovoRx | Effector Therapeutics vs. Ensysce Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Fundamental Analysis View fundamental data based on most recent published financial statements |